The results revealed that upregulation of DDX17 promoted HCC proliferation, migration, and invasion, whereas Reparixin treatment significantly abolished the DDX17-enhanced HCC-indicated abilities in vitro (Fig. 7A, B). Here, DDX17 is linked to hepatocellular carcinoma.